South and Central America RNAi Therapeutics Market
The South and Central America RNAi Therapeutics Market size was valued at US$ 21.22 Mn in 2019 and is projected to reach US$ 38.70 Mn by 2027, growing at a CAGR of 7.9% during 2019 - 2027.
Report Coverage
- Molecule Type: Small Interfering RNAs, MicroRNA
- Application: Genetic Disorders, Oncology, Neurodegenerative Disorders, Cardiovascular, Respiratory Disorders, Infectious Diseases, Renal Diseases
- Route of Administration: Intradermal Injections, Pulmonary Delivery, Intravenous Injections, Intraperitoneal Injections
- End User: Diagnostic Laboratories, Research and Academic Laboratories, Hospitals
US$ 21.22 Mn
Market size in 2019
US$ 38.70 Mn
Market Size by 2027
7.9%
CAGR, 2019 - 2027
2020-2027
Forecast Period
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. South and Central America RNAi Therapeutics Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. South and Central America RNAi Therapeutics Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. South and Central America RNAi Therapeutics Market Regional Analysis
6.2 South and Central America RNAi Therapeutics Market Revenue 2017-2027 (US$ Million)
6.3 South and Central America RNAi Therapeutics Market Forecast Analysis
7. South and Central America RNAi Therapeutics Market Analysis – by Molecule Type
7.1 Small Interfering RNAs
- 7.1.1 Overview
- 7.1.2 Small Interfering RNAs: South and Central America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.2 MicroRNA
- 7.2.1 Overview
- 7.2.2 MicroRNA: South and Central America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
8. South and Central America RNAi Therapeutics Market Analysis – by Application
8.1 Genetic Disorders
- 8.1.1 Overview
- 8.1.2 Genetic Disorders: South and Central America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.2 Oncology
- 8.2.1 Overview
- 8.2.2 Oncology: South and Central America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.3 Neurodegenerative Disorders
- 8.3.1 Overview
- 8.3.2 Neurodegenerative Disorders: South and Central America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.4 Cardiovascular
- 8.4.1 Overview
- 8.4.2 Cardiovascular: South and Central America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.5 Respiratory Disorders
- 8.5.1 Overview
- 8.5.2 Respiratory Disorders: South and Central America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.6 Infectious Diseases
- 8.6.1 Overview
- 8.6.2 Infectious Diseases: South and Central America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.7 Renal Diseases
- 8.7.1 Overview
- 8.7.2 Renal Diseases: South and Central America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
9. South and Central America RNAi Therapeutics Market Analysis – by Route of Administration
9.1 Intradermal Injections
- 9.1.1 Overview
- 9.1.2 Intradermal Injections: South and Central America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.2 Pulmonary Delivery
- 9.2.1 Overview
- 9.2.2 Pulmonary Delivery: South and Central America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.3 Intravenous Injections
- 9.3.1 Overview
- 9.3.2 Intravenous Injections: South and Central America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.4 Intraperitoneal Injections
- 9.4.1 Overview
- 9.4.2 Intraperitoneal Injections: South and Central America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
10. South and Central America RNAi Therapeutics Market Analysis – by End User
10.1 Diagnostic Laboratories
- 10.1.1 Overview
- 10.1.2 Diagnostic Laboratories: South and Central America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
10.2 Research and Academic Laboratories
- 10.2.1 Overview
- 10.2.2 Research and Academic Laboratories: South and Central America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
10.3 Hospitals
- 10.3.1 Overview
- 10.3.2 Hospitals: South and Central America RNAi Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
11. South and Central America RNAi Therapeutics Market – South and Central America Analysis
11.1 Overview
11.2 South and Central America- 11.2.1 South and Central America RNAi Therapeutics Market Breakdown, by Key Country, 2020 and 2027 (%)
- 11.2.1.1 South and Central America RNAi Therapeutics Market – Revenue and Forecast Analysis – by Country
- 11.2.1.1 Brazil: South and Central America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
- 11.2.1.1.1 Brazil: South and Central America RNAi Therapeutics Market Breakdown, by Molecule Type
- 11.2.1.1.2 Brazil: South and Central America RNAi Therapeutics Market Breakdown, by Application
- 11.2.1.1.3 Brazil: South and Central America RNAi Therapeutics Market Breakdown, by Route of Administration
- 11.2.1.1.4 Brazil: South and Central America RNAi Therapeutics Market Breakdown, by End User
- 11.2.1.2 Argentina: South and Central America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
- 11.2.1.2.1 Argentina: South and Central America RNAi Therapeutics Market Breakdown, by Molecule Type
- 11.2.1.2.2 Argentina: South and Central America RNAi Therapeutics Market Breakdown, by Application
- 11.2.1.2.3 Argentina: South and Central America RNAi Therapeutics Market Breakdown, by Route of Administration
- 11.2.1.2.4 Argentina: South and Central America RNAi Therapeutics Market Breakdown, by End User
- 11.2.1.3 Rest of South and Central America : South and Central America RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
- 11.2.1.3.1 Rest of South and Central America : South and Central America RNAi Therapeutics Market Breakdown, by Molecule Type
- 11.2.1.3.2 Rest of South and Central America : South and Central America RNAi Therapeutics Market Breakdown, by Application
- 11.2.1.3.3 Rest of South and Central America : South and Central America RNAi Therapeutics Market Breakdown, by Route of Administration
- 11.2.1.3.4 Rest of South and Central America : South and Central America RNAi Therapeutics Market Breakdown, by End User
12. Competitive Landscape
12.1 Heat Map Analysis
12.2 Company Positioning and Concentration
13. Industry Landscape
13.1 Overview
13.2 Market Initiative
13.3 Partnerships and Collaborations
13.4 Other Developments
14. Company Profiles
14.1 Quark
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Rexahn Pharmaceuticals, Inc
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Arbutus Biopharma
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Alnylam Pharmaceuticals, Inc
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Arrowhead Pharmaceuticals, Inc.
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
15. Appendix
15.1 About Business Market Insights
15.2 List of Abbreviations
Access the Full S Market Report
Get segment-level forecasts, regional estimates, competitive benchmarking, company profiles and downloadable Excel datasets.
